ClinicalTrials.gg
Active, not recruitingNCT04984369Updated Aug 21, 2023

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

A Phase 2 interventional study of HLX208 and Cetuximab Injection [Erbitux] in CRC, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF V600E Mutation after first-line treatment

02

Conditions studied

  • CRC
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=18Y
  • Good Organ Function
  • Expected survival time ≥ 3 months
  • /recurrent advanced BRAF+ mCRC that have been diagnosed histologically and have failed treatment
  • score 0-1;

Exclusion criteria

Exclusion Criteria:

  • arm 1 : Previous treatment with BRAF inhibitors or MEK inhibitors
  • Symptomatic brain or meningeal (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
  • Active clinical severe infection;
  • A history of other within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Never use other BRAF inhibitor therapy

    Never use other BRAF inhibitor therapy

    Drug: HLX208 · Drug: Cetuximab Injection [Erbitux]

  • Experimental
    PD after other BRAF inhibitor therapy N=5~40

    PD after other BRAF inhibitor therapy

    Drug: HLX208 · Drug: Cetuximab Injection [Erbitux]

  • Experimental
    SD but intolerant after other BRAF inhibitor therapy

    SD but intolerant after other BRAF inhibitor therapy

    Drug: HLX208 · Drug: Cetuximab Injection [Erbitux]

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1)

    Time frame: up to 2 years

Secondary outcomes

  1. PFS

    Progression-free survival (PFS) (assessed by IRRC and the investigator as per RECIST v1.1 )

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years]

  2. OS

    Overall survival

    Time frame: from the date of first dose until the date of death from any cause,assessed up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Jun 2024, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Jul 30, 2021
StartActual
Aug 11, 2021
Primary completionEst.
Jun 15, 2024
CompletionEst.
Jan 15, 2025
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04984369
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Aug 11, 2021
Primary completion
Jun 15, 2024 (estimated)
Completion
Jan 15, 2025 (estimated)
Last update
Aug 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion